Innate Pharma

Innate Pharma announces its financial calendar for 2017

January 4, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows: March 7, 2017 : Publication of 2016 financial statements...

Innate Pharma reports Third Quarter 2025 business update and financial results

November 13, 2025

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502 Nectin-4...

Innate Pharma announces FDA clearance to proceed with TELLOMAK 3, a confirmatory Phase 3 trial of lacutamab in CTCL

November 10, 2025

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of...

Innate Pharma announces conference call and webcast for Third quarter 2025 results and business updates

November 5, 2025

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m...

Fabrice Barlesi et al, 2024. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer Future oncology

Future Oncology

Read more about Future Oncology

Innate Pharma to host analyst and investor event on lacutamab on October 28, 2025

October 14, 2025

The event will provide clinical perspectives and market outlook for lacutamab, Innate’s lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase 3...